HCP5 and renal cell carcinoma: For example, LncRNA NR2F1-AS1 is associatedwith the oxaliplatin resistance in hepatocellular carcinoma [38]; lncARSR can promote the resistance to sunitinib in renal cell carcinoma [39]; LncRNA NORAD accelerates the progression of neuroblastoma and resistance to adriamycin through upregulation of HDAC8 [40]; lncRNA-HCP5 accelerates the progression of neuroblastoma and the resistance to adriamycin through miR-3619- 5p/AMPK/PGCAα/CEBPB axis which drives fatty acid oxidation, which in turn promotes stem cell features and the resistance to FOLFOX regimen in gastric cancer [41].